Breaking News, Financial News

Financial Report: Genentech

Genentech

1Q Revenues: $2.8 billion (+43%)

1Q Income: $706 million (+68%)

Comments: U.S. sales rose 30% to $2.0 billion, driven by growth in Avastin sales (+34% to $533 million) and Rituxan (+12% to $535 million). R&D costs increased 63% to $610 million, including $33 million in stock-based compensation for employees.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters